[ad_1]
The name of the new entity will be announced at a later date.
Waleed Al Mokarrab Al Muhairi, Chairman of Mubadala Health and Deputy Chief Executive Officer of Mubadala, said: “The future of healthcare lies in the incredible and rapidly evolving advancements in technology. The area of ​​expertise provides UAE residents with the highest standard of patient care.
“We now seek to take patient care to the next level, entering a new era of precision and personalized medicine.”
While Mubadala brings healthcare assets that are already well known, G42 brings its extensive R&D and AI capabilities into the mix. The alliance also has ambitions to go global by expanding possibilities.
Hasan Jasem Al Nowais has been appointed CEO of the new entity and will continue to lead Mubadala Health, whose assets include the Cleveland Clinic in Abu Dhabi, Moorfields Eye Hospital in Abu Dhabi and the Imperial College London Diabetes Centre.
“Our goal is to leverage the respective advantages of G42 Medical and Mubadala Medical to unlock medical super-intelligence and facilitate the expansion of global healthcare business,” said Xiao Peng, CEO of G42 Group. Our capabilities and experience will allow us to continue to transform the traditional healthcare ecosystem, delivering best-in-class patient care in world-class facilities, driven by the latest breakthrough research.”
G42’s presence in healthcare is represented by the UAE’s Omics Centre for Excellence and Insight Research Organisations and Solutions (IROS), the first UAE contract research organisation to specialise in healthcare research.
The new company represents a truly integrated healthcare ecosystem where research, technology, artificial intelligence and genomics combine with world-class care to optimize clinical outcomes.We are committed to ensuring our exceptional team of physicians and caregivers have access to groundbreaking medical technologies and provide patients with unparalleled care
– Hasan Jasem Al Nowais, CEO of Mubadala Health and the newly established company
[ad_2]
Source link